9.2 Postpartum Hormonal Contraception & Intrauterine Devices

Combined Hormonal Contraception (CHCs) & Postpartum Thromboembolism

Combined Hormonal Contraceptives (oral contraceptive pills, transdermal norelgestromin/ethinyl estradiol patch, and etonogestrel/ethinyl estradiol vaginal ring) carry significant puerperal restrictions due to two distinct pharmacological risks:

1. Venous Thromboembolism (VTE) Risk: The postpartum state is an independent, profound prothrombotic state. Baseline VTE risk is 20- to 80-fold higher than in non-pregnant, non-postpartum individuals, peaking sharply in the first 21 days. Exogenous estrogens stimulate hepatic production of fibrinogen, factor VII, factor VIII, and factor X, while suppressing endogenous protein S and antithrombin III. Introducing exogenous estrogen during the first 3 weeks compounds this hypercoagulability, creating an unacceptable risk of deep vein thrombosis, pulmonary embolism, and cerebral venous thrombosis.
2. Suppression of Lactogenesis: Exogenous ethinyl estradiol competitively antagonizes prolactin receptors and impairs mammary alveolar responsiveness, particularly during Lactogenesis II (days 2–5). This can severely curtail milk supply and shorten overall breastfeeding duration.

Clinical Prescribing Algorithm for CHCs

• <21 Days Postpartum: Category 4 (Absolute Contraindication) for ALL women, regardless of infant feeding choice.
• 21 to 42 Days Postpartum:
  • Non-breastfeeding women WITHOUT VTE risk factors: Category 2 (Generally safe).
  • Non-breastfeeding women WITH VTE risk factors: Category 3 (Risks outweigh benefits). Risk factors include: age ≥35 years, pre-pregnancy BMI ≥30 kg/m², cesarean delivery, postpartum hemorrhage, preeclampsia, smoking, immobility, or known inherited thrombophilia.
  • Breastfeeding women: Category 3 (due to potential suppression of milk volume).
• >42 Days (>6 Weeks) Postpartum: Category 1 (Unrestricted, unless preexisting medical contraindications exist).

---

Progestin-Only Methods: Immediate Postpartum Safety

Unlike estrogens, progestins do not alter hepatic synthesis of procoagulant proteins and do not increase VTE risk. Furthermore, extensive clinical trials confirm that progestins do not impair Lactogenesis II or III, do not diminish milk volume, and do not affect infant growth or neurodevelopment.

1. Progestin-Only Pills (POPs)

• Formulations:
  • Norethindrone (0.35 mg daily): Thickens cervical mucus within 2 to 4 hours of ingestion and suppresses ovulation in ~50% of cycles. Strict Adherence Window: Must be taken at the exact same time every day. If taken more than 3 hours late, a backup barrier method (e.g., condoms) is mandatory for 48 hours.
  • Drospirenone (4 mg daily, Slynd): Suppresses ovulation consistently; features a 24-hour missed pill window, providing greater user forgiveness.
• Timing: Can be initiated immediately postpartum on Day 1 (US MEC Category 1).

2. Depot Medroxyprogesterone Acetate (DMPA / Depo-Provera)

• Dosing: 150 mg deep intramuscular injection (gluteal or deltoid) or 104 mg subcutaneous injection every 13 weeks (with a 2-week grace period up to 15 weeks).
• Clinical Advantages: Highly effective, user-independent, private, and compatible with antiepileptic enzyme-inducing drugs.
• Counseling Pearls: Common side effects include unpredictable irregular spotting during the first 6 to 12 months, eventual amenorrhea (in 50% by 1 year), transient loss of bone mineral density (reversible upon cessation), and potential delay in return of fertility averaging 9 to 10 months after discontinuation.

3. Etonogestrel Subdermal Implant (Nexplanon)

• Profile: A single 4-cm rod containing 68 mg of etonogestrel placed subdermally in the inner non-dominant upper arm. Provides >99.9% contraceptive efficacy for up to 3 to 5 years by suppressing ovulation and thickening cervical mucus.
• Immediate Postpartum Placement: Highly recommended by ACOG and ACNM for insertion prior to hospital discharge. Immediate placement eliminates barriers to outpatient follow-up and does not impair lactogenesis. The primary side effect is unpredictable, irregular bleeding patterns, which requires thorough anticipatory counseling.

---

Intrauterine Devices (IUDs): Protocols & Expulsion Dynamics

Intrauterine contraception—including the copper T380A IUD (ParaGard; hormone-free, 10–12 years) and levonorgestrel-releasing IUDs (LNG-52 mg [Mirena, Liletta; 8 years], LNG-19.5 mg [Kyleena; 5 years])—represents the most effective reversible contraceptive modality.

                    [ Postpartum IUD Insertion Timing Windows ]
                                        │
         ┌──────────────────────────────┼──────────────────────────────┐
         ▼                              ▼                              ▼
[ Immediate Postplacental ]      [ Early Postpartum ]         [ Delayed Interval ]
Within 10 min of placenta        10 min to 48 hours           ≥4 to 6 weeks
Vaginal or Cesarean birth        Prior to hospital discharge  Full uterine involution
Expulsion rate: ~10%–15%         Expulsion rate: ~10%–15%     Expulsion rate: ~2%–5%
Category 1 / 2                   Category 1 / 2               Category 1

Timing Categories & Expulsion Kinetics

1. Immediate Postplacental Insertion: Placed within 10 minutes of placental expulsion (during a vaginal birth or at the time of cesarean hysterotomy closure).
2. Early Postpartum Insertion: Placed between 10 minutes and 48 hours postpartum prior to discharge.
3. Intermediate Window (48 Hours to 4 Weeks): Relative contraindication (US MEC Category 2 or 3). During this period, the rapidly involuting myometrium is soft, friable, and vascular, leading to heightened risks of uterine perforation and high expulsion rates. Insertion is generally deferred until ≥4 weeks.
4. Delayed Interval Insertion: Placed at or after 4 to 6 weeks postpartum, once uterine involution is near completion.

The Expulsion vs. Access Paradigm

• Expulsion Risk: Immediate postplacental and early postpartum IUD placement carries a clinically recognized expulsion rate of approximately 10% to 15% (compared to 2% to 5% for delayed interval placement).
• Clinical Midwifery Rationale: Despite higher expulsion rates, major clinical guidelines (ACOG, ACNM, CDC, WHO) strongly advocate for immediate postpartum LARC. In standard obstetric populations, up to 40% to 50% of postpartum individuals never return for their 6-week postpartum visit, leaving them at imminent risk for rapid repeat unintended pregnancy. Providing IUD insertion before discharge ensures 100% access, immediate contraception, and high overall 12-month continuation rates (>80%). Patients are counseled on expulsion signs and scheduled for string checks.
• Absolute Contraindication: Puerperal sepsis, chorioamnionitis, or active, unexplained postpartum hemorrhage is US MEC Category 4 (Strictly Contraindicated).

---